Skip to main content
. 2019 Aug 13;15(Suppl 4):45. doi: 10.1186/s13223-019-0355-0

Table 3.

Treatment on demand in patients with HAE-nlC1-INH

Total
(32/143 = 22.3%)
HAE-F12
(24/116 = 19.8%)
HAE-Unknown
(8/25 = 28%)
n % n % n %
Icatibant 7 21.9 3 12.5 4 50.0
C1-inhibitor 3 9.4 1 4.2 2 25.0
Tranexamic acid 25 78.1 21 87.5 4 50.0
Danazol 1 3.1 0 1 12.5